Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, IL, USA.
Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.
Eur J Ophthalmol. 2022 Jan;32(1):322-326. doi: 10.1177/1120672121998913. Epub 2021 Mar 2.
To assess the effectiveness and safety of adjunctive topical netarsudil 0.02% and latanoprostene bunod 0.024% in patients with glaucoma.
A retrospective, multi-center, cohort study of patients with glaucoma treated with netarsudil 0.02% or latanoprostene bunod from five tertiary care centers. Inclusion criteria included patients with glaucoma treated with either medication as adjunctive therapy. Outcomes included mean absolute intraocular pressure (IOP) reduction and relative IOP reduction from baseline. Adverse reactions and reasons for discontinuation were reported. One-way analysis of variance, Kruskal-Wallis rank sum test, and Mann Whitney test compared the outcomes.
A total of 95 eyes (95 patients) on netarsudil and 41 eyes (41 patients) on latanoprostene bunod were analyzed. Mean duration of use was 54.3 ± 28 days for netarsudil and 82.9 ± 51.2 days for latanoprostene bunod. At the final visit, mean IOP reduction was 3.9 ± 4.6 mmHg (17.5 ± 6.0%) ( < 0.0001) with netarsudil and 2.9 ± 3.7 mmHg (13.6 ± 16.3%) ( < 0.0001) with latanoprostene bunod. IOP lowering did not depend on baseline number of IOP-lowering medications. The most common reason for discontinuation was non-effectiveness in both groups.
Similar to monotherapy, netarsudil and latanoprostene bunod demonstrated efficacy in lowering IOP when used as adjunctive therapy.
评估曲伏前列素噻吗洛尔（netarsudil 0.02%）和拉坦前列素丁二酸（latanoprostene bunod 0.024%）联合治疗青光眼的有效性和安全性。
这是一项回顾性、多中心、队列研究，纳入了在五个三级保健中心接受曲伏前列素噻吗洛尔或拉坦前列素丁二酸治疗的青光眼患者。纳入标准为接受两种药物中的任意一种作为辅助治疗的青光眼患者。主要结局为治疗后平均绝对眼压（IOP）降低值和与基线相比的相对 IOP 降低值。同时报告不良反应和停药原因。采用单因素方差分析、Kruskal-Wallis 秩和检验和 Mann Whitney U 检验对各项结局进行比较。
共纳入 95 只眼（95 例患者）接受曲伏前列素噻吗洛尔治疗，41 只眼（41 例患者）接受拉坦前列素丁二酸治疗。曲伏前列素噻吗洛尔组的平均使用时间为 54.3±28 天，拉坦前列素丁二酸组为 82.9±51.2 天。末次随访时，曲伏前列素噻吗洛尔组的平均 IOP 降低值为 3.9±4.6mmHg（17.5±6.0%）（ < 0.0001），拉坦前列素丁二酸组为 2.9±3.7mmHg（13.6±16.3%）（ < 0.0001）。IOP 降低值与基线降 IOP 药物数量无关。两组最常见的停药原因均为无效。
与单药治疗相似，曲伏前列素噻吗洛尔和拉坦前列素丁二酸作为辅助治疗时均可有效降低 IOP。
